Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KROSNASDAQ:SAGENASDAQ:STRONASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$13.47-2.0%$12.27$9.12▼$72.37$558.05M1.32823,086 shs537,980 shsSAGESage Therapeutics$6.61-2.1%$7.49$4.62▼$13.47$413.93M0.21.22 million shs877,656 shsSTROSutro Biopharma$0.82-6.3%$0.83$0.52▼$5.17$68.76M1.771.10 million shs1.16 million shsUPBUpstream Bio$8.65-8.9%$8.06$5.14▼$29.46$465.32MN/A324,885 shs321,024 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics-1.97%-2.11%+10.59%+32.06%-75.06%SAGESage Therapeutics-2.07%-3.64%-7.68%-7.68%-45.66%STROSutro Biopharma-6.31%-14.21%+35.31%-49.37%-80.73%UPBUpstream Bio-8.95%+5.36%+17.37%+20.81%+864,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKROSKeros Therapeutics3.3276 of 5 stars4.31.00.00.02.95.00.0SAGESage Therapeutics3.7701 of 5 stars3.02.00.04.01.91.71.3STROSutro Biopharma4.168 of 5 stars4.12.00.04.71.41.70.6UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKROSKeros Therapeutics 2.57Moderate Buy$37.00174.68% UpsideSAGESage Therapeutics 2.00Hold$8.8133.32% UpsideSTROSutro Biopharma 2.22Hold$6.63712.78% UpsideUPBUpstream Bio 3.00Buy$56.50553.18% UpsideCurrent Analyst Ratings BreakdownLatest STRO, UPB, SAGE, and KROS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/9/2025KROSKeros TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$43.00 ➝ $25.004/1/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.004/1/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/17/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$12.00 ➝ $2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/14/2025STROSutro BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKROSKeros Therapeutics$214.71M2.55N/AN/A$11.09 per share1.21SAGESage Therapeutics$47.40M8.73N/AN/A$7.56 per share0.87STROSutro Biopharma$66.43M1.04N/AN/A$2.45 per share0.33UPBUpstream Bio$2.30M202.66N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKROSKeros Therapeutics-$152.99M-$0.18N/AN/AN/A-27,890.94%-41.74%-38.42%5/14/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)STROSutro Biopharma-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%N/AUPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest STRO, UPB, SAGE, and KROS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KROSKeros Therapeutics$0.1614N/AN/AN/A$62.01 millionN/A5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 million5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million3/13/2025Q4 2024STROSutro Biopharma-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million2/26/2025Q4 2024KROSKeros Therapeutics-$1.36-$1.14+$0.22-$1.14$37.32 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKROSKeros TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKROSKeros TherapeuticsN/A19.0319.03SAGESage TherapeuticsN/A7.427.42STROSutro BiopharmaN/A3.093.09UPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKROSKeros Therapeutics71.56%SAGESage Therapeutics99.22%STROSutro Biopharma96.99%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipKROSKeros Therapeutics22.90%SAGESage Therapeutics5.50%STROSutro Biopharma3.60%UPBUpstream BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKROSKeros Therapeutics10040.62 million31.23 millionOptionableSAGESage Therapeutics69062.62 million58.10 millionOptionableSTROSutro Biopharma24084.36 million77.59 millionOptionableUPBUpstream Bio3853.79 millionN/AN/ASTRO, UPB, SAGE, and KROS HeadlinesRecent News About These CompaniesBalyasny Asset Management L.P. Invests $4.95 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 13 at 5:14 AM | marketbeat.comEnavate Sciences GP LLC Acquires Shares of 2,459,703 Upstream Bio, Inc. (NASDAQ:UPB)May 11 at 8:04 AM | marketbeat.comQ2 EPS Estimates for Upstream Bio Decreased by William BlairMay 10, 2025 | marketbeat.comDeep Track Capital LP Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Invests $1.40 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comUpstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial PositionMay 6, 2025 | tipranks.comUpstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsMay 6, 2025 | globenewswire.comSamsara BioCapital LLC Acquires Shares of 2,217,146 Upstream Bio, Inc. (NASDAQ:UPB)May 2, 2025 | marketbeat.comSoros Fund Management LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)May 2, 2025 | marketbeat.comTCG Crossover Management LLC Takes $44.86 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)May 1, 2025 | marketbeat.comNantahala Capital Management LLC Acquires Shares of 600,000 Upstream Bio, Inc. (NASDAQ:UPB)April 30, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB)April 30, 2025 | marketbeat.comLynx1 Capital Management LP Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 29, 2025 | marketbeat.comDecheng Capital LLC Buys Shares of 3,285,293 Upstream Bio, Inc. (NASDAQ:UPB)April 28, 2025 | marketbeat.comGeode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 28, 2025 | marketbeat.comMarshall Wace LLP Makes New $4.78 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 27, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 7.2% Higher - Here's What HappenedApril 23, 2025 | marketbeat.comBain Capital Life Sciences Investors LLC Acquires New Holdings in Upstream Bio, Inc. (NASDAQ:UPB)April 23, 2025 | marketbeat.comUpstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentApril 17, 2025 | seekingalpha.comFmr LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceWhy NVIDIA Stock Could Soar Despite Wall Street DowngradesBy Thomas Hughes | April 14, 2025View Why NVIDIA Stock Could Soar Despite Wall Street DowngradesAMD Stock Signals Strong Buy Ahead of EarningsBy Thomas Hughes | May 1, 2025View AMD Stock Signals Strong Buy Ahead of EarningsThe 5 Top Buys for May: Strong Signals at Critical Support LevelsBy Thomas Hughes | April 30, 2025View The 5 Top Buys for May: Strong Signals at Critical Support LevelsPalantir Stock Drops Despite Stellar Earnings: What's Next?By Chris Markoch | May 6, 2025View Palantir Stock Drops Despite Stellar Earnings: What's Next?STRO, UPB, SAGE, and KROS Company DescriptionsKeros Therapeutics NASDAQ:KROS$13.47 -0.27 (-1.97%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$13.68 +0.22 (+1.60%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Sage Therapeutics NASDAQ:SAGE$6.61 -0.14 (-2.07%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$6.60 -0.01 (-0.15%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Sutro Biopharma NASDAQ:STRO$0.82 -0.05 (-6.31%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$0.84 +0.02 (+2.69%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Upstream Bio NASDAQ:UPB$8.65 -0.85 (-8.95%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$8.12 -0.54 (-6.18%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
